GLAXOSMITHKLINE BIOLOGICALS SA

Their core work

GSK Biologicals is the vaccines division of GlaxoSmithKline, headquartered in Rixensart, Belgium — one of the world's largest dedicated vaccine R&D and manufacturing sites. They develop, test, and manufacture vaccines against infectious diseases including Ebola, RSV, pertussis, influenza, and salmonella. In H2020, they contributed deep expertise in vaccine clinical development, manufacturing quality control, disease burden assessment, and biomarker discovery across 13 projects. Their work spans the full vaccine lifecycle from early-stage discovery through to real-world effectiveness monitoring and public health impact modelling.

What they specialise in

How they've shifted over time

In 2014–2018, GSK Bio focused on core vaccine R&D: Ebola vaccine clinical development (their only coordinated project), pertussis biomarker discovery, RSV epidemiology, and TB vaccine candidates — largely laboratory and discovery-oriented work. From 2019 onward, the focus shifted decisively toward population-level impact: vaccination in elderly populations, cost-benefit analyses, public health communication, and modelling how vaccines and monoclonal antibodies reduce antimicrobial resistance. This reflects a maturation from "can we build these vaccines?" to "how do we prove and communicate their societal value?"

GSK Bio is moving toward health economics, real-world evidence, and AMR modelling — future collaborators should expect interest in demonstrating vaccine value beyond clinical efficacy.

How they like to work

GSK Bio overwhelmingly participates as a partner rather than leading consortia — they coordinated only 1 of 13 projects (EbolaVac, likely due to proprietary vaccine technology). They consistently join large, multi-country IMI and RIA consortia (173 unique partners across 30 countries), acting as the industry anchor that brings proprietary data, clinical trial infrastructure, and regulatory know-how. This is typical of Big Pharma in public-private partnerships: they contribute resources and data access but let academic or public-sector partners lead.

With 173 unique consortium partners across 30 countries, GSK Bio has one of the broadest collaboration networks in European vaccine research. Their partnerships span academic medical centres, public health institutes, and regulatory bodies across virtually all EU member states and associated countries.

What sets them apart

GSK Bio is one of the few global vaccine manufacturers deeply embedded in European public-private research partnerships. Unlike academic partners, they bring proprietary vaccine platforms, GMP manufacturing capability, and regulatory submission experience — meaning research conducted with them has a realistic path to market. Their dual presence as both participant and third party across IMI projects signals that multiple GSK entities contribute specialized capabilities, making them a comprehensive industry partner for the full vaccine development pipeline.

Highlights from their portfolio

• EbolaVac
  GSK Bio's only coordinated project with EUR 14.1M in EC funding — developed a chimpanzee adenovirus-based Ebola vaccine during the 2014 West Africa crisis, demonstrating rapid-response vaccine capability.
• RESCEU
  Flagship RSV consortium (2017-2022) that built the epidemiological evidence base now underpinning Europe's RSV immunisation strategies — directly tied to GSK's RSV vaccine pipeline.
• PrIMAVeRa
  Signals GSK Bio's strategic pivot into antimicrobial resistance modelling, connecting vaccine and monoclonal antibody impact to the AMR crisis — a politically high-priority area for future EU funding.